Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Supernus Pharmaceuticals ...

    NASDAQ: SUPN · Real-Time Price · USD
    31.14
    -0.06 (-0.19%)
    At close: Jun 27, 2025, 3:59 PM
    31.16
    0.06%
    After-hours: Jun 27, 2025, 04:34 PM EDT

    Supernus Pharmaceuticals Statistics

    Share Statistics

    Supernus Pharmaceuticals has 55.99M shares outstanding. The number of shares has increased by 1.53% in one year.

    Shares Outstanding

    n/a
    		 55.99M

    Shares Change (YoY)

    n/a
    		 1.53%

    Shares Change (QoQ)

    n/a
    		 1.08%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 52.98M

    Failed to Deliver (FTD) Shares

    n/a
    		 42

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 4.23M, so 7.57% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.23M

    Short % of Shares Out

    n/a
    		 7.57%

    Short % of Float

    n/a
    		 11.46%

    Short Ratio (days to cover)

    n/a
    		 9.83

    Valuation Ratios

    The PE ratio is 26.97 and the forward PE ratio is 13.23. Supernus Pharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 26.97

    Forward PE

    n/a
    		 13.23

    PS Ratio

    n/a
    		 3.01

    Forward PS

    n/a
    		 1.7

    PB Ratio

    n/a
    		 1.92

    P/FCF Ratio

    n/a
    		 11.64

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Supernus Pharmaceuticals has an Enterprise Value (EV) of 1.96B.

    EV / Sales

    n/a
    		 2.96

    EV / EBITDA

    n/a
    		 10.98

    EV / EBIT

    n/a
    		 11.38

    EV / FCF

    n/a
    		 11.43

    Financial Position

    The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 2.35

    Quick Ratio

    n/a
    		 2.16

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 0.19

    Debt / FCF

    n/a
    		 0.2

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 7.13% and Return on Invested Capital is 5.69%.

    Return on Equity

    n/a
    		 7.13%

    Return on Assets

    n/a
    		 5.4%

    Return on Invested Capital

    n/a
    		 5.69%

    Revenue Per Employee

    n/a
    		 $981,924.33

    Profits Per Employee

    n/a
    		 $109,591.99

    Employee Count

    n/a
    		 674

    Asset Turnover

    n/a
    		 0.48

    Inventory Turnover

    n/a
    		 1.43

    Taxes

    Income Tax

    n/a
    		 24M

    Effective Tax Rate

    n/a
    		 24.53%

    Stock Price Statistics

    The stock price has increased by 16.15% in the last 52 weeks. The beta is 0.71, so Supernus Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.71

    52-Week Price Change

    n/a
    		 16.15%

    50-Day Moving Average

    n/a
    		 32.11

    200-Day Moving Average

    n/a
    		 34.04

    Relative Strength Index (RSI)

    n/a
    		 39.22

    Average Volume (20 Days)

    n/a
    		 535,891

    Income Statement

    In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M and earned 73.86M in profits. Earnings per share was 1.34.

    Revenue

    n/a
    		 661.82M

    Gross Profit

    n/a
    		 583.91M

    Operating Income

    n/a
    		 81.67M

    Net Income

    n/a
    		 73.86M

    EBITDA

    n/a
    		 178.28M

    EBIT

    n/a
    		 97.87M

    Earnings Per Share (EPS)

    n/a
    		 1.34
    Full Income Statement

    Balance Sheet

    The company has 69.33M in cash and 34.27M in debt, giving a net cash position of 35.06M.

    Cash & Cash Equivalents

    n/a
    		 69.33M

    Total Debt

    n/a
    		 34.27M

    Net Cash

    n/a
    		 35.06M

    Retained Earnings

    n/a
    		 556.43M

    Total Assets

    n/a
    		 1.35B

    Working Capital

    n/a
    		 405.81M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 171.95M and capital expenditures -725K, giving a free cash flow of 171.23M.

    Operating Cash Flow

    n/a
    		 171.95M

    Capital Expenditures

    n/a
    		 -725K

    Free Cash Flow

    n/a
    		 171.23M

    FCF Per Share

    n/a
    		 3.11
    Full Cash Flow Statement

    Margins

    Gross margin is 88.23%, with operating and profit margins of 12.34% and 11.16%.

    Gross Margin

    n/a
    		 88.23%

    Operating Margin

    n/a
    		 12.34%

    Pretax Margin

    n/a
    		 14.79%

    Profit Margin

    n/a
    		 11.16%

    EBITDA Margin

    n/a
    		 26.94%

    EBIT Margin

    n/a
    		 12.34%

    FCF Margin

    n/a
    		 25.87%

    Dividends & Yields

    SUPN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 3.71%

    FCF Yield

    n/a
    		 8.59%
    Dividend Details

    Analyst Forecast

    The average price target for SUPN is $36, which is 15.3% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $36

    Price Target Difference

    n/a
    		 15.3%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $6.7

    Lynch Upside

    n/a
    		 -78.53%

    Graham Number

    n/a
    		 23.81

    Graham Upside

    n/a
    		 -23.71%

    Scores

    Altman Z-Score

    n/a
    		 5

    Piotroski F-Score

    n/a
    		 7

    Add to Watchlist